2.6  0 (0%)		10-04 10:38
Open: 2.68 High: 2.69 Volume: 4,429		Pre. Close: 2.6 Low: 2.6 Market Cap: 62(M)

Short term
Mid term
Targets	6-month :	3.82	1-year :	4.37
Resists	First :	3.27	Second :	3.74
Pivot price	2.75
Supports	First :	2.5	Second :	2.08
MAs	MA(5) :	2.68	MA(20) :	2.87
	MA(100) :	3.27	MA(250) :	2.35
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	13.3	D(3) :	15.7
RSI	RSI(14): 40
52-week	High :	5.98	Low :	0.81

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MAIA ] has closed above bottom band by 18.3%. Bollinger Bands are 54.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.76 - 2.77	2.77 - 2.78
Low:	2.55 - 2.57	2.57 - 2.59
Close:	2.57 - 2.6	2.6 - 2.63

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Thu, 03 Oct 2024
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Down 1.1% - MarketBeat

Tue, 10 Sep 2024
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Yahoo Finance

Wed, 04 Sep 2024
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Wed, 04 Sep 2024
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance

Tue, 23 Jul 2024
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - Benzinga

Tue, 23 Jul 2024
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	24 (M)
Shares Float	19 (M)
Held by Insiders	16.3 (%)
Held by Institutions	7.4 (%)
Shares Short	633 (K)
Shares Short P.Month	777 (K)

EPS	-1.63
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.12
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-107.2 %
Return on Equity (ttm)	-559.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-1.61
PEG Ratio	0
Price to Book value	20
Price to Sales	0
Price to Cash Flow	-4.04

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.